Annually over 200 million adults undergo noncardiac surgery worldwide.
Epidemiology
Worldwide over 200 million adults undergo non cardiac surgery annually [1, 2] . Conservative estimates suggest that at least 100 million adults undergoing noncardiac surgery are in an atrisk age group for majo r perioperative vascular events [3] . Approximately 8 million of these patients will suffer a myocardial in jury after noncardiac surgery (MINS) [4] and, as a result, over 1 million adults will die within 30 days of non cardiac surgery worldwide annually [1, 2] . The magni tude of this problem is predicted to increase owing in part to an aging population, a rise in the incidence of cardiovascular related problems, and a trend toward surgical intervention in elderly patients.
Myocardial infarction (MI) is defined in the Third Uni
versal Definition of Myocardial Infarction, an expert consensus document by the global Myocardial Infarc tion Task Force [5] (table 1) . While MI is the cardiac end point in many perioperative studies, it is important to differentiate MINS from MI as a multitude of factors limit the ability to diagnose an MI in the perioperative period (table 1) .
Typically, postoperative patients receive some form of analgesia. This is often an opioid or similar agent, which can effectively mask chest pain from myo cardial ischaemia [6] . Furthermore, patients who are sedated or intubated postoperatively are unable to effectively communicate and thus perioperative ischaemia may be overlooked. The majority of troponin measure ments and ECGs are ordered on the basis of ischaemic symptoms [7] , therefore acute perioperative MI or MINS may be missed in patients receiving analgesia or in patients whose communication is impaired.
Based on the VISION Study (a prospective, inter natio nal, cohort study involving 40 000 patients, ≥45 years of age having noncardiac surgery), the majority of patients (87%) with MINS experienced the ischaemic Table 1 : Definition of myocardial infarction (MI) and myocardial injury after noncardiac surgery (MINS).
MI
Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac troponin) with at least one value above the 99th percentile upper reference limit and with at least one of the following: -Symptoms of ischaemia -New or presumed new significant ST-segment-T wave changes or new left bundle-branch block -Development of pathological Q waves in the ECG -Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality -Identification of an intracoronary thrombus by angiography or autopsy [5] .
MINS
A prognostically relevant myocardial injury due to ischaemia.
-The diagnostic criterion for MINS is troponin T ≥0.03 ng/ml due to an ischaemic aetiology within 30 days of noncardiac surgery. -Ischaemic ECG changes are not required.
-Ischaemic cardiac symptoms are not required [4] .
injury within the first 3 days after surgery [4] . A mere 15.8% of patients who developed MINS experienced ischaemic cardiac symptoms [4] . Therefore, without postoperative troponin monitoring, 84.2% of MINS events would go undetected [4] . Furthermore, in VISION, all patients with an elevated troponin meas urement had an ECG. Only 34.9% of patients had ischaemic ECG changes and a minority (41.8%) of patients suffering MINS fulfilled the universal defini tion of MI ( fig. 1) [4] .
115-129 mm Hg were randomised to antihypertensive drugs or placebo [9] . The followup period was 18 months. At the time, many experts believed that hypertension was essential for brain perfusion. The primary outcome included death, dissecting/ruptured aortic aneurysm, cerebral haemorrhage / disabling stroke, MI, congestive heart failure (CHF), retinal haemorrhage, papilloedema and rapidly progressive renal failure [9] . Thirtynine percent of the placebo group versus three percent of the antihypertensive group experienced the primary outcome. The relative risk reduction for antihypertensive drugs was 93%, p = 0.00000003 [9] .
Historically, physicians did not believe that non valvular atrial fibrillation was a risk factor for stroke, but rather simply a nuisance for patients who experi enced palpitations [10, 11] . Currently, it is recognised that both valvular and nonvalvular atrial fibrillation carry a significant risk of embolic stroke. [4] . The PAR represents the proportion of all deaths potentially attributable to the relevant risk factor (e.g., MINS) if causality was proven [12] .
Higher levels of postoperative troponin T elevation correlate with increased risk of mortality. In VISIO N, MINS: myocardial injury after noncardiac surgery; MI: myocardial infarction. Adapted from [7] , reprint with permission.
At risk noncardiac surgery patients

MI
In the POISE Trial (an international βblocker trial of 8351 patients who underwent noncardiac surgery), only 34.7% of patients with perioperative MI experienced symptoms of ischaemia [8] . Therefore, the absence of reported ischaemic cardiac symptoms and imperfect timing of the ECG (e.g., ECG performed in response to a detected elevated troponin on routine screening but after the acute ischaemic event) may result in a missed diagnosis of perioperative MI or MINS [7] .
Historical perspective
In 1967, JAMA published the VA Hypertension Trial in which US veterans with diastolic blood pressure of [12] . The median time from discharge to death was 11 days (IQR 4-15 days) and 26.6% of the patients who died, did so after hospital discharge [12] . Therefore, MINS may serve as a "red flag" or foreshadowing of a more serious vascular event to follow in the next 30 days and up to 1 year after noncardiac surgery [12, 13] .
Pathophysiology of perioperative MI and MINS
The precise pathophysiology of perioperative MI and
MINS
has not yet been clearly defined. The two pre dominant theories involve myocardial oxygen supplydemand mismatch [15] , and coronary artery thrombo sis [1, 16] .
Multiple factors may increase myocardial oxygen demand perioperatively including fluid shifts, catechol amine surges, hypotension, anaemia, pain, hypo thermia and hypoxia [17] . In coronary arteries with highgrade lesions, the inability to respond adequately to increas e d myocardial oxygen demand may lead to supply-demand mismatch resulting in myo cardial ischaemia [1] . Thus, preexisting coronary artery disease (CAD) is an intuitive culprit. However, in an angio graphic study involving vascular surgery patients, the majority of MINS occurred in myocar dium supplied by arteries without highgrade stenosis [18] . The landmark CARP Trial (510 patients) demon strated no reduction in perioperative MI with pre operative revascularisation for coronary stenosis ≥70% forgo an operation if they deem the risk of a major pe rioperative cardiac complication unacceptable, or they may opt to defer the procedure (e.g., to experience an important life event) [31] . MINS is an independent pre dictor of death [12] , and the risk remains elevated up to a year post operatively [13] . 
Evidence-based perioperative pharmacology
Increased sympathetic drive increases a patient's heart rate and hence myocardial demand, which may lead to myocardial oxygen supply-demand mismatch. More over, it can also induce a hypercoaguable state [23] [24] [25] and catecholamine release that increases shear stress [33] . This may trigger plaque rupture and acute coro nary syndromes (ACS) perioperatively [33] . Thus, in an attempt to prevent MINS or major adverse cardiac events (MACE) in the perioperative setting, various agents including βblockers, α2adrenergic antagonists, statins and aspirin (acetylsalicylic acid, ASA) have been trialed to reduce the sympathetic response [8, 34] , stabilise coronary plaque [35] or to inhibit platelet function [8, 36] .
Beta-blockers
Betablockers were proposed as a potential cardiopro tective agent in the perioperative period [37] . A small trial in the 1990s found that βblockers had a large effect in preventing perioperative MI; however, it had methodological limitations including not performing an intenttotreat analysis [37] . [40] . Given the association with increased mortality and stroke, current guidelines no longer recommend initiation of βblocker therapy in the perioperative period [8, [40] [41] [42] .
Aspirin
Noncardiac surgery is associated with platelet activa tion [43] . ASA inhibits thrombus formation and obser vational data had suggested that discontinuation of ASA prior to surgery would result in increased throm botic risk [44, 45] . A systematic review and two small
RCTs showed mixed results but with a potential decreased risk of vascular events in patients on ASA in the perioperative period [46] [47] [48] . In contrast, the PEP trial, involving 13 356 patients undergoing hip surgery, demonstrated more cardiac ischaemic events (death due to ischaemic heart disease or nonfatal MI) in patients randomised to ASA versus placebo (HR 1.33, 95% CI 1.00-1.78) [49] . There was also an increased risk of bleeding (6 per 1000 patients) [49] . This was driven by a statistically significant lower risk of MINS and death [52] . This relative effect corre sponded to an absolute risk reduction of 2.0% (95% CI 0.5-3.2%, p = 0.005). VISION is the only study to look at the association of statin use with MINS, and the results are hypothesis generating in that preoperative statin use may reduce the risk of adverse perioperative car diac outcomes [52] . A large RCT is required to evaluate these findings further.
Alpha-2 adrenergic agonists
Results of small RCTs initially suggested that clonidine (an α2adrenergic agonist) may prevent MI [53, 54] by blunting central sympathetic outflow with associated anxiolytic, and antiinflammatory effects [54, 55] . How ever, these trials were small (<300 patients) with few events [53] [54] [55] [56] . A metaanalysis of 12 RCTs looking at α2adrenergic agonists in noncardiac surgery showed no difference in overall mortality or MI in the entire study population; however, a decrease in MI and death was found in the vascular surgery subgroup [57] . These findings were driven largely by a trial from 1999 that used mivazerol, an α2adrenergic agonist [56, 57] .
More recently, POISE 2, found that clonidine did not reduce the rate of death or nonfatal MI at 30 days (HR perioperative hypotension is an independent risk fac tor for perioperative MI [34, 58] . Thus, in the largest trial in this area, α2 adrenergic agonists were not pro tective and increased the risk of significant periopera tive hypotension and bradycardia [34] .
Perioperative hypotension
POISE demonstrated that clinically significant hypo tension (defined as systolic blood pressure <90 mm Hg requiring intervention) had the largest PAR (37.3%) for perioperative death and the largest PAR for stroke (14.7%) [8] . In POISE 2, more patients in the clonidine group had clinically important hypotension, brady cardia and an increased risk of nonfatal cardiac arrest [34] . Prospective observational studies have suggest e d an association between intraoperative hypo tension with myocardial injury [59, 60] and 30day mortality [58] . A recent cohort study on perioperative hypo 
Treatment options for MINS
Data that informs on the optimal treatment for MINS patients is limited; however, extrapolation from the ACS literature [61, 62] 
Conclusion
MINS is common and is associated with poor out comes. One in ten patients suffering from MINS will die in 30 days after noncardiac surgery [12] . Failure to monitor troponin after noncardiac surgery will miss over 80% of MINS events [12] .
The current model of perioperative patient care lacks continuity of care, and it is easy to assume that pa tients do well postoperatively if they are not followed 
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